Healthy Participants, Pharmacokinetics, Safety, Tolerability
Conditions
Keywords
First-in-Human, Placebo-controlled, AZD7503, Single Ascending Dose, Sentinel Dosing
Brief summary
This study will evaluate safety, tolerability and pharmacokinetics (PK) of AZD7503, following subcutaneous (SC) administration of single ascending doses of AZD7503 in healthy participants.
Detailed description
This is a Phase I, First-in-Human, study in healthy males and females (non-childbearing potential) participants. In this study up to four dose levels of AZD7503 are planned to be evaluated. The planned doses of AZD7503 are dose 1, dose 2, dose 3, and dose 4. Eligible participants will be randomised to receive either AZD7503 or placebo. The study will include four single dose cohorts with an option to include two cohorts based on emerging data from planned cohorts in the study and two additional cohorts of Japanese participants and one cohort of Chinese participants will also be included. Dosing for each ascending dose cohort will be proceeded with sentinel dosing strategy. Here, sentinel sub-cohort will be included, such that 1 participant will be randomised to receive placebo and 1 participant will be randomised to receive AZD7503. The safety data from the sentinel participants up to 24 hours post-dose will be reviewed by the Principal Investigator (PI) before the remaining participants in the cohort are dosed The study will comprise: * A Screening Period of maximum 28 days; * A Treatment Period during which participants will be resident at the Study Centre from the day before study medication administration (Day -1) until at least 72 hours after study medication administration; discharged from the Study Centre on Day 4; * Follow-up Visits on 1,2,4,6 and 8 weeks; and * A Final Follow-up Visit 10 weeks after the last study medication dose. Each participant will be involved in the study for approximately 14 weeks.
Interventions
DRUGAZD7503
Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).
DRUGPlacebo
Randomised participants will receive placebo by SC injection
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Masking description
This study is single blind with regard to treatment (AZD7503 or placebo). This means that the participant and the study centre staff will remain blinded during the dosing phase of the study and the randomisation code will only be available at each pre defined decision point before the Safety Review Committee meeting in order to review the data unblinded.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy non smoking male and/or female (of non childbearing potential) participants with suitable veins for cannulation or repeated venipuncture. * Females must have a negative pregnancy test at screening and on admission to the study centre, must not be lactating and must be of non childbearing potential. * Body mass index (BMI) between 18 and 30 kg/m\^2, inclusive, and weigh at least 60 kg for healthy participants or between 18 and 32 kg/m\^2, inclusive, and weigh at least 50 kg for Japanese and Chinese participants. * For Japanese and Chinese participants: 1. A Japanese participant is defined as having both parents and 4 grandparents who are ethnically Japanese. This includes first-, second-and third-generation Japanese whose parents or grandparents are living in a country other than Japan. 2. A Chinese participant is defined as having both parents and 4 grandparents who are ethnically Chinese. This includes first-, second-and third-generation Chinese whose parents or grandparents are living in a country other than China. * Willing to participate in retrospective genotyping analysis for HSD17B13.
Exclusion criteria
* History of any clinically important disease or disorder. * History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs. * Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of administration of study intervention. * Any laboratory values with the following deviations at screening and/or Day 1: * Alanine aminotransferase \> Upper Limit of Normal (ULN) * Aspartate aminotransferase \> ULN * Total bilirubin \> ULN * Creatinine \> ULN * White blood cell count \< Lower Limit of Normal (LLN) * Hemoglobin \< LLN * Estimated glomerular filtration rate \< 60 mL/min/1.73 m\^2 * Platelets \>ULN and/or \<LLN. * Any clinically important abnormalities in clinical chemistry, hematology or urinalysis results other than those described above, including participants with platelet or bleeding disorders, known platelet dysfunction disorders. * Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody or Human Immunodeficiency Virus. * Confirmed coronavirus disease 2019 (COVID-19) infection during screening and/or admission by polymerase chain reaction (PCR) test. * Abnormal vital signs, after 5 minutes supine rest * Any clinically important abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically important abnormalities in the 12 lead ECG. * Current smokers or those who have smoked or used nicotine products (including e cigarettes) within the previous 3 months. * History of alcohol abuse or excessive intake of alcohol * History of Drug abuse or positive screen for drug of abuse or cotinine (nicotine) or alcohol. * History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity or history of hypersensitivity to drugs with a similar chemical structure or class to AZD7503. * Excessive intake of caffeine containing drinks or food (eg, coffee, tea, chocolate) * Use of any prescribed or non prescribed medication during the 2 weeks prior to the administration of study intervention or longer if the medication has a long half-life. * Plasma donation within one month of screening or any blood donation/blood loss more than 500 mL during the 3 months prior to screening. * Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days (or 5 half lives, whichever is longer) of the administration of study intervention in this study. * Any ongoing or recent (ie, during the screening period) minor medical complaints. * Previous bone marrow transplant. * Non leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with Adverse Events (AEs) | Up to Final Follow-up (FU) Visit (Week 10) or Early Termination (ET) (assessed up to 14 Weeks) | To assess adverse events as a variable of safety and tolerability of AZD7503 following SC single dose administration. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast) of AZD7503 | (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks) | To characterise the PK (AUClast) of AZD7503 following SC administration of single ascending doses of AZD7503. |
| Maximum observed plasma (peak) drug concentration (Cmax) of AZD7503 | (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks) | To characterise the PK (Cmax) of AZD7503 following SC administration of single ascending doses of AZD7503. |
| Time to reach peak or maximum observed concentration or response following drug administration (tmax) of AZD7503 | (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks) | To characterise the PK (tmax) of AZD7503 following SC administration of single ascending doses of AZD7503. |
| Time of last observed (quantifiable) concentration (tlast) of AZD7503 | (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks) | To characterise the PK (tlast) of AZD7503 following SC administration of single ascending doses of AZD7503. |
| Partial area under the plasma concentration-time curve from time 0 to time 48 hours post dose [AUC(0-48)] of AZD7503 | (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks) | To characterise the PK \[AUC(0-48)\] of AZD7503 following SC administration of single ascending doses of AZD7503. |
| Half-life associated with terminal slope (λz) of a semi logarithmic concentration time curve (t½λz) of AZD7503 | (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks) | To characterise the PK (t½λz) of AZD7503 following SC administration of single ascending doses of AZD7503. |
| Area under plasma concentration time-curve from zero to infinity (AUCinf) of AZD7503 | (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks) | To characterise the PK (AUCinf) of AZD7503 following SC administration of single ascending doses of AZD7503. |
| Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of AZD7503 | (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks) | To characterise the PK (CL/F) of AZD7503 following SC administration of single ascending doses of AZD7503. |
| Apparent volume of distribution at steady state following extravascular administration (Vz/F) of AZD7503 | (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks) | To characterise the PK (Vz/F) of AZD7503 following SC administration of single ascending doses of AZD7503. |
| Cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1-t2)] of AZD7503 | (Pre-dose and Post-dose) Days 1 to 4 | To characterise the PK \[Ae(t1-t2)\] of AZD7503 following SC administration of single ascending doses of AZD7503. |
| Percentage of dose excreted unchanged in urine from time t1 to t2 [Fe(t1-t2)] of AZD7503 | (Pre-dose and Post-dose) Days 1 to 4 | To characterise the PK \[Fe(t1-t2)\] of AZD7503 following SC administration of single ascending doses of AZD7503. |
| Renal clearance of drug from plasma (CLR) of AZD7503 | (Pre-dose and Post-dose) Days 1 to 4 | To characterise the PK (CLR) of AZD7503 following SC administration of single ascending doses of AZD7503. |
| Number of participants with positive anti-drug antibodies (ADA) of AZD7503 | Day -1 to final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks) | To explore the formation of ADAs. |
| Mean residence time of the unchanged drug in the systemic circulation (MRTinf) of AZD7503 | (Pre-dose and Post-dose) Days 1 to 4 and final FU visit (Week 10 post last dose) or ET (assessed up to 14 Weeks) | To characterise the PK (MRTinf) of AZD7503 following SC administration of single ascending doses of AZD7503. |
Countries
United States
Outcome results
None listed